Overview
Tony Moody, MD is a Professor in the Department of Pediatrics, Division of Infectious Diseases and Professor in the Department of Integrative Immunobiology at Duke University Medical Center. Research in the Moody lab is focused on understanding the B cell responses during infection, vaccination, and disease. The lab has become a resource for human phenotyping, flow characterization, staining and analysis at the Duke Human Vaccine Institute (DHVI). The Moody lab is currently funded to study influenza, syphilis, HIV-1, and emerging infectious diseases.
Dr. Moody is the director of the Duke CIVICs Vaccine Center (DCVC) at (DHVI) and co-director of the Centers for Research of Emerging Infectious Disease Coordinating Center (CREID-CC). Dr. Moody is mPI of a U01 program to develop a syphilis vaccine; this program is a collaboration with mPI Dr. Justin Radolf at the University of Connecticut. Dr. Moody is also the director of the DHVI Accessioning Unit, a biorepository that provides support for work occurring at DHVI and with its many collaborators around the world by providing processing, shipping, and inventory support for a wide array of projects.
Dr. Moody and his team are involved in many networks studying vaccine response including the Collaborative Influenza Vaccine Innovation Centers (CIVICs) and the COVID-19 Prevention Network (CoVPN).
Current Appointments & Affiliations
Recent Publications
Validation of prototype virus inactivation from seven virus families of pandemic potential with a novel low-cost, field-deployable RNA extraction and storage method.
Journal Article J Virol Methods · February 2026 The Centers for Research in Emerging Infectious Diseases (CREID) was established to enhance pandemic preparedness by studying emerging/reemerging pathogens, especially in resource-limited regions. To overcome infrastructure challenges, a low-cost, field-de ... Full text Link to item CiteGene discovery and expression analysis of the B cell receptor repertoire in the domestic ferret model.
Journal Article Vaccine · October 3, 2025 The domestic ferret is the preferred model organism for the study of influenza A infection and responses to vaccination, because its respiratory tract architecture and sialic acid receptor type and distribution are similar to those in humans. Despite this, ... Full text Link to item CiteQualification of a reporter virus microneutralization assay for evaluation of influenza specific antibodies in human clinical trials.
Journal Article Vaccine · October 3, 2025 Neutralizing antibodies can block the entry of viruses into host cells. Next-generation influenza vaccines should stimulate the production of high levels of neutralizing antibodies capable of preventing influenza infection or reducing the severity of disea ... Full text Link to item CiteRecent Grants
Interdisciplinary Research Training Program in AIDS
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2010 - 20302/3 CTSA K12 Program at Duke University
ResearchMentor · Awarded by National Institutes of Health · 2025 - 2030Unified Program for Therapeutics in Children
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2025 - 2030View All Grants